Print

Executive Insights

Volume XVII, Issue 14 | April 13, 2015 | By: Chris Kenney, Robert Rourke, Darren Perry

In this Executive Insights, L.E.K addresses the “danger zones,” or challenges facing industrial distributors if they do not differentiate, lack adequate scale, fail to build their ecommerce presence or acquiesce to manufacturers with broad downstream resources. Those who respond or reposition themselves while taking the necessary steps to boost their capabilities in ecommerce, marketing and product support will gain competitive advantages and be well positioned to improve profitability. 

Volume XVII, Issue 13 | April 6, 2015 | By: Joseph Johnson

In this Executive Insights, L.E.K. Consulting examines how HCIT companies can crack the code to achieve maximum commercial potential and take advantage of the seismic changes overturning healthcare in the United States.

Volume XVII, Issue 12 | March 27, 2015 | By: Bill Frack, Wiley Bell

As payers seek partnerships with a narrower group of providers who can deliver real value, providers must take on greater financial risk and demonstrate continuous improvements in patient outcomes. New risk models can lead to increased reward, but are also fraught with danger for all parties in the movement toward value-based care (VBC). In this Executive Insights, L.E.K. discusses key success factors that should be considered before going forward with a new value-based model.

Volume XVII, Issue 11 | March 23, 2015 | By: Diogo Silva, Peter Ward

It’s always been difficult for "challenger banks" to compete with the U.K.’s largest players. In the past, they have failed to move the needle in either retail or corporate banking. However, thanks to recent regulatory and market conditions, a new generation of challengers have entered the market. In this Executive Insights L.E.K. Consulting's Diogo Silva and Peter Ward explain why challenger banks should focus on the underserved U.K. SME market and set out a strategy to enable them to take full advantage of this opportunity.

Volume XVII, Issue 10 | March 11, 2015 | By: Robert Rourke, Thilo Henkes, Darren Perry

L.E.K. Consulting’s annual Contractor Behavior Survey revealed a continued positive recovery in the construction industry more notably this year as contractors once again reported healthier margins and sustained growth, and showed an ongoing resolve with respect to pricing new projects. The survey also emphasized a preference for one-stepper, broadline or specialty dealers over big-box stores and home improvement centers.

Volume XVII, Issue 9 | March 5, 2015 | By: Arnaud Sergent, Serge Hovsepian, Ben Faircloth

In this Executive Insights, L.E.K. Consulting's Arnaud Sergent, Serge Hovsepian and Ben Faircloth examine the opportunities and risks in the outsourced manufacturing market, and identify four specialization strategies that CMOs can adopt in order to build a differentiated and successful business in this buoyant but complex market.

Volume XVII, Issue 8 | March 4, 2015 | By: Eilert Hinrichs, Peter Ward

In this Executive Insights, L.E.K. Consulting's Eilert Hinrichs and Peter Ward identify the mistakes so often made by new entrants to the European Debt Purchasers (DPs) markets, before setting out the lessons and explaining the winning strategies of DPs who have successfully expanded in Europe.

Volume XVII, Issue 7 | March 3, 2015 | By: Sue St. Sure, Nurry Hong

Pharma and biotech executives need to think as much about drug delivery as they do about research and development, so L.E.K. Consulting has devised a three-step process of realization: Is a drug delivery strategy important to your organization? Will a one-off approach suffice or do you need a platform? Which technologies matter for the drugs in your pipeline? Those that can get drug delivery right in this evolving biologics landscape will capture crucial share in the marketplace.

2015 State of the Industry | March 1, 2015 | By: David Barrow

Executives in the MedTech industry face many critical strategic questions in 2015. To help navigate the road ahead, L.E.K. Consulting shares its views on the current state of the industry, as well as the biggest challenges and opportunities for MedTech companies.

2015 State of the Industry | March 1, 2015

Executives in the biopharma and life sciences industry face many critical strategic questions in 2015. Here, L.E.K. Consulting shares its views on the key challenges and opportunities for life sciences companies, as well as the solutions that senior executives are already turning to.

Pages